Lack/NN
of/IN
Association/NN
of/IN
BIRC5/NN
Polymorphisms/NNS
with/IN
Clearance/NN
of/IN
HBV/NN
Infection/NN
and/CC
HCC/NN
Occurrence/NN
in/IN
a/DT
Korean/JJ
Population/NN
./.
====================
BIRC5/CD
(/(
Survivin/NN
)/)
belongs/VBZ
to/TO
the/DT
inhibitor/NN
of/IN
apoptosis/NN
gene/NN
family/NN
./.
====================
The/DT
BIRC5/NN
protein/NN
inhibits/VBZ
caspases/NNS
and/CC
consequently/RB
blocks/VBZ
apoptosis/NN
./.
====================
Thus/RB
,/,
BIRC5/NN
contributes/VBZ
to/TO
the/DT
progression/NN
of/IN
cancer/NN
allowing/VBG
for/IN
continued/JJ
cell/NN
proliferation/NN
and/CC
survival/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
eight/CD
sequence/NN
variants/NNS
of/IN
BIRC5/NN
through/IN
direct/JJ
DNA/NN
sequencing/NN
./.
====================
Among/IN
the/DT
eight/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
,/,
six/CD
common/JJ
variants/NNS
with/IN
frequencies/NNS
higher/JJR
than/IN
0.05/CD
were/VBD
selected/VBN
for/IN
largerscale/JJ
genotyping/VBG
(/(
n=1,066/CD
)/)
./.
====================
Results/NNS
of/IN
the/DT
study/NN
did/VBD
not/RB
show/VB
any/DT
association/NN
between/IN
the/DT
promoter/NN
region/NN
polymorphisms/NNS
and/CC
the/DT
clearance/NN
of/IN
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
infection/NN
and/CC
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
occurrence/VBP
./.
====================
This/DT
is/VBZ
in/IN
line/NN
with/IN
a/DT
previous/JJ
study/NN
in/IN
which/WDT
polymorphisms/NNS
in/IN
the/DT
promoter/NN
region/NN
does/VBZ
not/RB
influence/VB
the/DT
function/NN
of/IN
BIRC5/NN
./.
====================
Initially/RB
,/,
we/PRP
were/VBD
able/JJ
to/TO
detect/VB
a/DT
signal/NN
with/IN
the/DT
＋9194A＞G/NN
,/,
which/WDT
disappeared/VBD
after/IN
multiple/JJ
corrections/NNS
but/CC
led/VBD
to/TO
a/DT
change/NN
in/IN
amino/NN
acid/NN
./.
====================
Similarly/RB
,/,
we/PRP
were/VBD
also/RB
able/JJ
to/TO
detect/VB
an/DT
association/NN
signal/NN
between/IN
two/CD
haplotypes/NNS
(/(
haplotype2/NN
and/CC
haplotype-5/NN
)/)
on/IN
the/DT
onset/NN
age/NN
of/IN
HCC/NN
and/or/CC
HCC/NN
occurrence/NN
,/,
but/CC
the/DT
signals/NNS
also/RB
disappeared/VBD
after/IN
multiple/JJ
corrections/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
concluded/VBD
that/IN
there/EX
was/VBD
no/DT
association/NN
between/IN
BIRC5/NN
polymorphisms/NNS
and/CC
the/DT
clearance/NN
HBV/NN
infection/NN
and/or/CC
HCC/NN
occurrence/NN
./.
====================
However/RB
,/,
our/PRP$
results/NNS
might/MD
useful/JJ
to/TO
future/JJ
studies/NNS
./.
====================
Hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
infection/NN
,/,
one/CD
of/IN
the/DT
most/JJS
common/JJ
virus/NN
infections/NNS
among/IN
humans/NNS
,/,
is/VBZ
the/DT
major/JJ
cause/VBP
of/IN
acute/JJ
and/CC
chronic/JJ
liver/NN
diseases/NNS
(/(
Lin/JJ
and/CC
Kao/NN
,/,
2008/CD
)/)
./.
====================
It/PRP
affects/VBZ
approximately/RB
350/CD
million/NN
people/NN
every/RB
year/NN
,/,
especially/RB
those/DT
in/IN
Asia/NN
,/,
Africa/NNP
,/,
Southern/NN
Europe/NN
,/,
and/CC
Latin/JJ
America/NN
(/(
Lok/JJ
and/CC
McMahon/NN
,/,
2007/CD
)/)
./.
====================
The/DT
clinical/JJ
courses/NNS
of/IN
HBV/NN
infection/NN
are/VBP
diverse/JJ
,/,
ranging/VBG
from/IN
spontaneous/JJ
recovery/NN
after/IN
hepatitis/NN
to/TO
a/DT
chronic/JJ
infection/NN
./.
====================
The/DT
risk/NN
of/IN
developing/VBG
liver/NN
cirrhosis/NN
(/(
LC/NN
)/)
or/CC
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
is/VBZ
higher/JJR
for/IN
those/DT
who/WP
happen/VBD
to/TO
be/VB
HBV/NN
chronic/JJ
carriers/NNS
as/IN
compared/VBN
to/TO
the/DT
uninfected/JJ
ones/NNS
(/(
Merican/NNP
,/,
Guan/NNP
et/FW
al/JJ
./.
====================
2000/CD
)/)
./.
====================
Several/JJ
previous/JJ
studies/NNS
on/IN
HBV/NN
infection/NN
have/VBP
reported/VBN
that/IN
polymorphisms/NNS
were/VBD
associated/VBN
with/IN
the/DT
risk/NN
of/IN
HCC/NN
and/or/CC
clearance/NN
of/IN
HBV/NN
(/(
Kida/NN
et/FW
al./FW
,/,
2007/CD
;/:
Kim/NN
et/FW
al./FW
,/,
2006/CD
;/:
Park/NN
et/FW
al./FW
,/,
2006/CD
;/:
Shin/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
BIRC5/CD
(/(
baculoviral/JJ
inhibitor/NN
of/IN
apoptosis/NN
repeatcontaning/VBG
5/CD
)/)
,/,
also/RB
known/VBN
as/IN
survivin/NN
,/,
is/VBZ
a/DT
protein/NN
encoded/VBN
by/IN
the/DT
BIRC5/NN
(/(
Altieri/FW
1994a/CD
;/:
Altieri/RB
1994b/CD
)/)
./.
====================
It/PRP
belongs/VBZ
to/TO
the/DT
inhibitor/NN
of/IN
apoptosis/NN
(/(
IAP/NN
)/)
gene/NN
family/NN
./.
====================
The/DT
BIRC5/NN
protein/NN
functions/VBZ
to/TO
inhibit/VB
caspase/NN
activation/NN
,/,
thus/RB
leading/VBG
to/TO
a/DT
decrease/NN
in/IN
apoptosis/NN
or/CC
programmed/VBN
cell/NN
death/NN
./.
====================
This/DT
has/VBZ
been/VBN
shown/VBN
by/IN
increase/NN
in/IN
apoptosis/NN
and/CC
decrease/NN
in/IN
tumor/NN
growth/NN
by/IN
disruption/NN
of/IN
BIRC5/NN
induction/NN
pathways/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
BIRC5/NN
protein/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
most/JJS
tumor/NN
cells/NNS
(/(
Sah/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Because/IN
of/IN
this/DT
,/,
BIRC5/NN
is/VBZ
considered/VBN
as/IN
one/CD
of/IN
the/DT
potent/JJ
target/NN
for/IN
cancer/NN
therapy/NN
(/(
Altieri/FW
,/,
2003/CD
)/)
./.
====================
A/DT
previous/JJ
study/NN
demonstrates/VBZ
that/IN
BIRC5/NN
is/VBZ
associated/VBN
with/IN
microtubules/NNS
of/IN
the/DT
mitotic/JJ
spindle/NN
at/IN
the/DT
start/NN
of/IN
mitosis/NN
through/IN
the/DT
disruption/NN
of/IN
microtubule/JJ
formation/NN
after/IN
BIRC5/NN
protein/NN
in/IN
cancer/NN
cells/NNS
are/VBP
knocked/VBN
out/IN
./.
====================
This/DT
appearance/NN
leads/VBZ
to/TO
polyploidy/NN
as/IN
well/RB
as/IN
massive/JJ
apoptosis/NN
(/(
Castedo/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Another/DT
study/NN
involves/VBZ
how/WRB
the/DT
BIRC5/NN
depleted/VBN
cells/NNS
exit/VBP
mitosis/NN
without/IN
achieving/VBG
proper/JJ
chromosome/NN
alignment/NN
and/CC
then/RB
reforms/VBZ
single/JJ
tetraploid/JJ
nuclei/NNS
./.
====================
It/PRP
suggests/VBZ
that/IN
BIRC5/NN
protein/NN
is/VBZ
needed/VBN
for/IN
sustaining/VBG
mitotic/JJ
arrest/NN
upon/IN
encounter/NN
with/IN
mitosis/NN
problems/NNS
./.
====================
The/DT
previous/JJ
studies/NNS
im/VBP
plicate/VBP
that/DT
BIRC5/NN
protein/NN
plays/VBZ
an/DT
important/JJ
regulatory/JJ
role/NN
both/CC
in/FW
the/DT
progression/NN
of/IN
mitosis/NN
and/CC
sustaining/VBG
mitotic/JJ
arrest/NN
(/(
Castedo/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Based/VBN
on/IN
those/DT
observations/NNS
in/IN
cancer/NN
development/NN
,/,
we/PRP
hypothesized/VBD
that/IN
BIRC5/NN
polymorphisms/NNS
may/MD
affect/VB
the/DT
function/NN
of/IN
BIRC5/NN
protein/NN
and/CC
influence/VBP
the/DT
clearance/NN
of/IN
HBV/NN
and/CC
HCC/NN
progression/NN
among/IN
HBVinfected/JJ
patients/NNS
thus/RB
,/,
conducting/VBG
a/DT
case-control/JJ
study/NN
on/IN
the/DT
BIRC5/NN
gene/NN
./.
====================
A/DT
total/JJ
of/IN
1,066/CD
Korean/JJ
subjects/NNS
having/VBG
either/CC
present/JJ
or/CC
past/JJ
evidences/VBZ
of/IN
HBV/NN
infection/NN
were/VBD
enrolled/VBN
from/IN
the/DT
outpatient/JJ
clinic/JJ
of/IN
the/DT
liver/NN
unit/NN
or/CC
from/IN
the/DT
Center/JJ
for/IN
Health/NN
Promotion/NN
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
./.
====================
Subjects/NNS
were/VBD
divided/VBN
into/IN
two/CD
different/JJ
groups/NNS
according/VBG
to/TO
serologic/JJ
markers/NNS
:/:
the/DT
chronic/JJ
carrier/NN
(/(
CC/NN
)/)
group/NN
,/,
and/CC
the/DT
spontaneous/JJ
recovery/NN
(/(
SR/JJ
)/)
group/NN
./.
====================
The/DT
CC/NN
and/CC
SR/JJ
cohorts/NNS
consisted/VBD
of/IN
632/CD
and/CC
434/CD
subjects/NNS
,/,
respectively/RB
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
diagnoses/NNS
of/IN
the/DT
CC/NN
and/CC
SR/JJ
subjects/NNS
were/VBD
established/VBN
by/IN
repeated/VBN
seropositivity/NN
for/IN
the/DT
hepatitis/NN
B/NN
surface/NN
antigen/NN
(/(
HBsAg/NN
)/)
(/(
EnzygnostⓇ/NNP
HBsAg/NN
5.0/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
over/IN
a/DT
6-month/JJ
period/NN
,/,
and/CC
for/IN
both/DT
anti-HBs/JJ
(/(
EnzygnostⓇ/NNP
Anti-HBs/JJ
II/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
and/CC
anti-HBc/JJ
(/(
AB-Corek/NNP
;/:
DiaSorin/NN
s./CC
r./NNP
l./FW
,/,
Saluggia/NNP
,/,
Italy/RB
)/)
of/IN
the/DT
IgG/NN
type/NN
without/IN
HBsAg/NN
,/,
respectively/RB
./.
====================
Asymptomatic/JJ
HBV/NN
carriers/NNS
,/,
which/WDT
usually/RB
involve/VBP
patients/NNS
with/IN
inactive/JJ
liver/NN
disease/NN
on/IN
liver/NN
biopsy/NN
,/,
were/VBD
also/RB
included/VBD
the/DT
in/FW
CC/NN
group/NN
./.
====================
However/RB
,/,
it/PRP
has/VBZ
been/VBN
known/VBN
that/IN
,/,
HBV/NN
continues/NNS
to/TO
replicate/VB
,/,
albeit/IN
at/IN
very/RB
low/JJ
levels/NNS
,/,
in/IN
some/DT
patients/NNS
that/WDT
have/VBP
residual/JJ
liver/NN
disease/NN
,/,
which/WDT
in/IN
most/JJS
cases/NNS
leads/VBZ
to/TO
the/DT
development/NN
of/IN
HCC/NN
./.
====================
We/PRP
excluded/VBD
subjects/NNS
who/WP
were/VBD
positive/JJ
for/IN
anti-HBs/JJ
but/CC
not/RB
for/IN
antiHBc/JJ
,/,
as/IN
well/RB
as/IN
those/DT
positive/JJ
for/IN
antiHCV/JJ
or/CC
antiHIV/JJ
(/(
GENEDIAⓇ/NNP
;/:
Greencross/NNP
Life/NN
Science/NNP
Corp./NNP
,/,
Yonginshi/NNP
,/,
Korea/NN
,/,
HCVⓇ3.2/NN
;/:
DongA/NNP
Pharmaceutical/JJ
Co./NNP
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Patients/NNS
who/WP
had/VBD
any/DT
other/JJ
types/NNS
of/IN
liver/NN
diseases/NNS
such/JJ
as/IN
autoimmune/JJ
hepatitis/NN
,/,
toxic/JJ
hepatitis/NN
,/,
primary/JJ
biliary/JJ
cirrhosis/NN
,/,
and/CC
BuddChiari/NNP
syndrome/NN
were/VBD
also/RB
excluded/VBN
from/IN
the/DT
study/NN
./.
====================
None/NN
of/IN
the/DT
patients/NNS
had/VBD
any/DT
previous/JJ
history/JJ
of/IN
immunosuppression/NN
or/CC
antiviral/JJ
treatment/NN
./.
====================
Informed/VBN
consent/JJ
was/VBD
obtained/VBN
from/IN
each/DT
patient/NN
,/,
and/CC
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Human/JJ
Research/NN
at/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
approved/JJ
the/DT
study/NN
protocol/NN
./.
====================
The/DT
clinical/JJ
parameters/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
Using/VBG
the/DT
ABI/NN
PRISM/NN
3700/CD
DNA/NN
analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
)/)
,/,
we/PRP
sequenced/VBD
exons/NNS
,/,
introns/NNS
,/,
and/CC
the/DT
promoter/NN
region/NN
(/(
∼1.5/CD
)/)
to/TO
discover/RB
variants/NNS
from/IN
24/CD
unrelated/JJ
individual/JJ
’/CD
s/NNS
DNA/NN
samples/NNS
./.
====================
Primer/NN
sets/NNS
for/IN
the/DT
amplification/NN
and/CC
sequencing/NN
analysis/NN
of/IN
BIRC5/NN
were/VBD
designed/VBN
based/VBN
on/IN
GenBank/NN
sequences/NNS
./.
====================
Sequence/NN
analysis/NN
was/VBD
carried/VBN
out/RP
using/VBG
SeqManⓇ/NN
software/JJ
./.
====================
Amplifying/VBG
primers/NNS
and/CC
probes/NNS
were/VBD
designed/VBN
for/IN
TaqManⓇ/NN
(/(
An/DT
et/FW
al./FW
,/,
2002/CD
)/)
which/WDT
was/VBD
used/VBN
for/IN
genotyping/VBG
of/IN
the/DT
six/CD
polymorphic/JJ
sites/NNS
./.
====================
Primer/NN
Express/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
was/VBD
used/VBN
to/TO
design/VB
both/CC
the/DT
PCR/NN
primers/NNS
and/CC
the/DT
MGB/NN
TaqMan/NN
probes/NNS
./.
====================
One/CD
allelic/JJ
probe/NN
was/VBD
labeled/VBN
with/IN
FAM/NN
dye/NN
and/CC
the/DT
other/JJ
with/IN
fluorescent/JJ
VIC/NN
dye/NN
./.
====================
Typically/RB
,/,
PCR/NN
was/VBD
run/JJ
in/IN
the/DT
TaqMan/NN
Universal/JJ
Master/NN
mix/JJ
without/IN
UNG/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
at/IN
primer/NN
concentration/NN
of/IN
900/CD
nM/NN
and/CC
TaqMan/NN
MGBprobe/NN
con/NN
centration/NN
of/IN
200/CD
nM/NN
./.
====================
The/DT
reaction/NN
was/VBD
performed/VBN
in/IN
a/DT
384-well/JJ
format/IN
with/IN
a/DT
total/JJ
reaction/NN
volume/NN
of/IN
5/CD
ul/NN
using/VBG
20/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
./.
====================
The/DT
plate/JJ
was/VBD
then/RB
placed/VBN
in/IN
a/DT
thermal/JJ
cycler/NN
(/(
PE/NN
9,700/CD
,/,
Applied/VBN
Biosystems/NNS
)/)
and/CC
was/VBD
heated/VBN
for/IN
2/CD
min/NN
at/IN
50oC/JJ
,/,
then/RB
for/IN
10/CD
min/NN
at/IN
95oC/JJ
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
95oC/JJ
for/IN
15/CD
sec/JJ
,/,
and/CC
finally/RB
60oC/JJ
for/IN
1/CD
min/NN
./.
====================
The/DT
TaqMan/NN
assay/NN
plate/VBP
was/VBD
then/RB
transferred/VBD
to/TO
a/DT
Prism/NN
7900HT/CD
instrument/JJ
(/(
Applied/VBN
Biosystems/NNS
)/)
where/WRB
the/DT
fluorescence/NN
intensity/NN
of/IN
each/DT
well/RB
was/VBD
read/VBN
./.
====================
Fluorescence/NN
data/NNS
files/NNS
from/IN
each/DT
plate/NN
were/VBD
analyzed/VBN
by/IN
automated/JJ
software/JJ
(/(
SDS/NN
2.1/CD
)/)
./.
====================
Detailed/JJ
information/NN
concerning/VBG
the/DT
primers/NNS
can/MD
be/VB
obtained/VBN
at/IN
the/DT
website/JJ
mentioned/JJ
above/JJ
./.
====================
We/PRP
examined/VBD
Lewontin/NN
’/CD
s/NNS
D/NN
’/CD
(/(
|D/NN
’/CD
|/CD
)/)
and/CC
LD/NN
coefficient/JJ
r2/NN
between/IN
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
(/(
Hedrick/JJ
,/,
1987/CD
)/)
./.
====================
Haplotypes/NNS
of/IN
each/DT
individual/JJ
were/VBD
determined/VBN
using/VBG
the/DT
algorithm/NN
developed/VBD
by/IN
Stephens/NNS
et/FW
al/JJ
./.
====================
(/(
Stephens/NNS
et/FW
al./FW
,/,
2001/CD
)/)
,/,
which/WDT
(/(
PHASE/NN
)/)
uses/VBZ
a/DT
Bayesian/JJ
approach/NN
incorporating/VBG
priori/JJ
expectations/NNS
of/IN
haplotypic/JJ
structure/NN
from/IN
population/NN
genetic/JJ
and/CC
coalescent/JJ
theory/JJ
./.
====================
Genetic/JJ
effects/NNS
of/IN
inferred/JJ
haplotypes/NNS
were/VBD
analyzed/VBN
in/IN
the/DT
same/JJ
way/NN
as/IN
SNPs/NNS
./.
====================
Logistic/JJ
regression/NN
models/NNS
were/VBD
used/VBN
for/IN
calculating/JJ
odds/NNS
ratios/NNS
(/(
95/CD
%/NN
confidential/JJ
interval/JJ
)/)
and/CC
corresponding/JJ
Pvalues/NNS
controlling/VBG
for/IN
age/NN
(/(
continuous/JJ
value/NN
)/)
and/CC
sex/NN
(/(
male=0/NN
,/,
female=1/NN
)/)
as/IN
covariates/VBZ
./.
====================
In/IN
our/PRP$
analysis/NN
on/IN
HCC/NN
occurrence/NN
,/,
LC/NN
(/(
LC=1/NN
,/,
no/DT
LC=0/NN
)/)
and/CC
HBeAg/NN
(/(
negative=0/CD
,/,
blank=1/NN
,/,
positive=2/NN
)/)
were/VBD
also/RB
used/VBN
as/IN
covariates/VBZ
./.
====================
Statistical/JJ
powers/NNS
were/VBD
also/RB
calculated/VBN
using/VBG
PGA/NN
matlab/NN
application/NN
(/(
Menashe/NNP
,/,
Rosenberg/NNP
et/FW
al/JJ
./.
====================
2008/CD
)/)
./.
====================
PGA/NN
is/VBZ
designed/VBN
to/TO
calculate/VB
statistical/JJ
power/JJR
and/CC
other/JJ
values/NNS
of/IN
casecontrol/JJ
genetic/JJ
association/NN
studies/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
codominant/JJ
(/(
1df/NN
)/)
model/NN
,/,
relative/JJ
risk/NN
1.3/CD
,/,
disease/NN
prevalence/NN
value/NN
7.1/CD
%/NN
(/(
Lee/NNP
,/,
Kim/NN
et/FW
al/JJ
./.
====================
1998/CD
)/)
,/,
EDF/NN
(/(
Effective/JJ
degree/NN
of/IN
freedom/JJ
)/)
2/CD
,/,
and/CC
alpha/NN
error/NN
level/NN
5/CD
%/NN
were/VBD
used/VBN
to/TO
calculate/JJ
the/DT
statistical/JJ
power/JJR
./.
====================
We/PRP
identified/VBD
eight/CD
genetic/JJ
variants/NNS
in/IN
BIRC5/NN
using/VBG
direct/JJ
sequencing/NN
from/IN
24/CD
unrelated/JJ
individuals/NNS
./.
====================
The/DT
range/NN
of/IN
direct/JJ
sequencing/NN
included/VBD
the/DT
promoter/NN
region/NN
,/,
as/IN
well/RB
as/IN
the/DT
introns/NNS
and/CC
exons/NNS
of/IN
BIRC5/NN
./.
====================
Among/IN
the/DT
eight/CD
genetic/JJ
variants/NNS
,/,
four/CD
SNPs/NNS
were/VBD
located/JJ
in/IN
the/DT
promoter/NN
region/NN
(/(
−1547T＞C/NN
,/,
−644T＞C/NN
,/,
−625G＞C/NN
,/,
−241C＞T/NN
)/)
,/,
one/CD
in/IN
exon/NN
4/CD
(/(
＋9194A＞G/NN
)/)
and/CC
three/CD
in/IN
3/CD
’/NN
UTR/NN
(/(
＋9386T＞C/NN
,/,
＋9625G＞A/NNP
,/,
＋9809T＞C/NN
)/)
,/,
respectively/RB
./.
====================
The/DT
frequencies/NNS
of/IN
each/DT
SNPs/NNS
were/VBD
0.216/CD
(/(
−1547T＞C/NN
)/)
,/,
0.277/CD
(/(
−644T＞C/NN
)/)
,/,
0.272/CD
(/(
−625G＞C/NN
)/)
,/,
0.021/CD
(/(
−241C＞T/NN
)/)
,/,
0.227/CD
(/(
＋9194A＞G/NN
)/)
,/,
0.236/CD
(/(
＋9386T＞C/NN
)/)
,/,
0.022/CD
(/(
＋9625G＞A/NNP
)/)
,/,
and/CC
0.395/CD
(/(
＋9809T＞C/NN
)/)
(/(
Fig/NN
./.
====================
1A/NN
,/,
Table/JJ
2/CD
)/)
./.
====================
The/DT
logistic/JJ
analysis/NN
for/IN
clearance/NN
of/IN
HBV/NN
infection/NN
,/,
HCC/NN
occurrence/NN
,/,
and/CC
onset/NN
age/NN
of/IN
HCC/NN
occurrence/NN
,/,
as/IN
well/RB
as/IN
the/DT
p-values/NNS
of/IN
each/DT
polymorphisms/NNS
,/,
haplotypes/NNS
,/,
and/CC
statistical/JJ
powers/NNS
are/VBP
displayed/VBN
in/IN
Table/JJ
3/CD
./.
====================
In/IN
the/DT
case/NN
of/IN
SNPs/NNS
,/,
among/IN
the/DT
eight/CD
variants/NNS
detected/VBN
by/IN
direct/JJ
sequencing/NN
,/,
six/CD
were/VBD
selected/VBN
for/IN
the/DT
association/NN
analysis/NN
of/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/CC
HCC/NN
occurrence/NN
./.
====================
Two/CD
SNPs/NNS
(/(
−241C＞T/NN
and/CC
＋9625G＞A/NN
)/)
were/VBD
excluded/VBN
from/IN
the/DT
analysis/NN
due/JJ
to/TO
low/JJ
frequencies/NNS
,/,
0.021/CD
and/CC
0.022/CD
respectively/RB
./.
====================
Among/IN
the/DT
six/CD
polymorphisms/NNS
,/,
−644T＞C/NN
in/IN
the/DT
promoter/NN
region/NN
showed/VBD
an/DT
association/NN
signal/NN
with/IN
HCC/NN
occurrence/NN
(/(
p=0.04/NN
)/)
and/CC
onset/NN
age/NN
of/IN
HCC/NN
(/(
p=0.05/NN
)/)
before/IN
correction/NN
was/VBD
conducted/VBN
,/,
whereas/IN
the/DT
other/JJ
SNPs/NNS
in/IN
the/DT
promoter/NN
regions/NNS
showed/VBD
no/DT
association/NN
signals/NNS
in/IN
all/DT
the/DT
analysis/NN
./.
====================
An/DT
association/NN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
before/IN
correction/NN
was/VBD
also/RB
detected/VBN
in/IN
＋9194A＞G/NN
(/(
p=0.04/NN
)/)
,/,
which/WDT
led/VBD
to/TO
a/DT
change/NN
in/IN
amino/NN
acid/NN
lysine/NN
to/TO
glutamate/VB
./.
====================
Another/DT
association/NN
analysis/NN
was/VBD
conducted/VBN
for/IN
haplotypes/NNS
./.
====================
Five/CD
haplotypes/NNS
with/IN
frequencies/NNS
greater/JJR
than/IN
5/CD
%/NN
were/VBD
selected/VBN
for/IN
analysis/NN
./.
====================
The/DT
selected/VBN
haplotypes/NNS
were/VBD
able/JJ
to/TO
explain/VB
more/RBR
than/IN
96/CD
%/NN
of/IN
the/DT
distribution/NN
(/(
Fig/NN
1B/NN
)/)
./.
====================
Linkage/JJ
disequilibrium/NN
coefficients/NNS
(/(
|D/NN
’/CD
|/CD
)/)
between/IN
all/DT
SNP/NN
pairs/NNS
were/VBD
also/RB
shown/VBN
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
Among/IN
the/DT
haplotypes/NNS
that/DT
we/PRP
selected/VBD
for/IN
analysis/NN
,/,
haplotype5/RB
[/(
TTGATC/NN
]/)
showed/VBD
an/DT
association/NN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
(/(
p=0.01/NN
)/)
and/CC
haplotype2/NN
[/(
TTGGTT/NN
]/)
showed/VBD
an/DT
association/NN
in/IN
onset/NN
age/NN
of/IN
HCC/NN
analysis/NN
(/(
p=0.03/NN
)/)
before/IN
correction/NN
Table/JJ
3/CD
./.
====================
BIRC5/CD
serves/VBZ
as/IN
a/DT
major/JJ
factor/NN
in/IN
cancer/NN
development/NN
by/IN
contributing/VBG
to/TO
the/DT
resistance/NN
of/IN
cancer/NN
cells/NNS
to/TO
apoptosis/NN
(/(
Hedrick/JJ
,/,
1987/CD
)/)
./.
====================
BIRC5/CD
has/VBZ
been/VBN
known/VBN
to/TO
be/VB
involved/VBN
in/IN
cellcycle/JJ
progression/NN
by/IN
bypassing/VBG
cellcycle/JJ
checkpoints/NNS
leading/VBG
to/TO
continued/JJ
proliferation/NN
(/(
Ambrosini/NNS
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
This/DT
can/MD
be/VB
explained/VBN
by/IN
the/DT
fact/NN
that/IN
tumor/NN
cells/NNS
can/MD
divide/VB
without/IN
breaking/VBG
and/CC
eventually/RB
survive/VBP
./.
====================
In/IN
addition/NN
,/,
a/DT
previous/JJ
study/NN
has/VBZ
reported/VBN
that/IN
the/DT
expression/NN
level/NN
of/IN
BIRC5/NN
in/IN
hepatocellular/JJ
carcinoma/NN
cells/NNS
is/VBZ
higher/JJR
than/IN
in/IN
other/JJ
cancercausing/JJ
cells/NNS
(/(
Montorsi/NNP
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
With/IN
the/DT
role/NN
played/VBD
by/IN
BIRC5/NN
in/IN
cancer/NN
development/NN
,/,
we/PRP
hypothesized/VBD
that/IN
BIRC5/NN
polymorphisms/NNS
were/VBD
associated/VBN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/or/CC
HCC/NN
occurrence/NN
./.
====================
Previous/JJ
studies/NNS
have/VBP
reported/VBN
three/CD
polymorphisms/NNS
(/(
−644T＞C/NN
,/,
−625G＞C/NNP
,/,
−31C＞G/NNP
)/)
involved/VBN
in/IN
the/DT
study/NN
of/IN
lung/NN
cancer/NN
in/IN
a/DT
Korean/JJ
population/NN
(/(
n=582/CD
)/)
(/(
Jang/NNP
et/FW
al./FW
,/,
2008/CD
)/)
and/CC
seven/CD
polymorphisms/NNS
(/(
−267G＞/NNP
A/DT
,/,
−241C＞T/NNP
,/,
−235G＞A/NNP
,/,
−198/CD
,/,
−191/CD
,/,
−141/CD
and/CC
−31C＞G/NN
)/)
studied/VBD
for/IN
breast/NN
carcinoma/NN
in/IN
a/DT
French/JJ
population/NN
(/(
n=191/CD
)/)
(/(
Boidot/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Among/IN
the/DT
promoter/NN
region/NN
polymorphisms/NNS
that/DT
were/VBD
studied/VBN
in/IN
both/DT
Korean/JJ
and/CC
French/JJ
populations/NNS
,/,
−31C＞G/NNP
has/VBZ
been/VBN
considered/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
cancer/NN
development/NN
by/IN
affecting/VBG
the/DT
expression/NN
level/NN
of/IN
mRNA/NN
of/IN
BIRC5/NN
(/(
Yang/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Furthermore/RB
,/,
two/CD
studies/NNS
concerning/VBG
cancer/NN
in/IN
Taiwan/JJ
and/CC
China/NN
populations/NNS
also/RB
examined/VBN
the/DT
−31C＞G/NN
polymorphism/NN
(/(
Wang/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Yang/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
In/IN
contrast/NN
,/,
one/CD
study/NN
reported/VBD
that/IN
the/DT
polymorphisms/NNS
in/IN
the/DT
promoter/NN
region/NN
,/,
including/VBG
−31C＜G/NN
does/VBZ
not/RB
have/VB
any/DT
influence/VBP
on/IN
the/DT
BIRC5/NN
activity/NN
(/(
Boidot/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Although/IN
−31C＞G/NN
was/VBD
not/RB
identified/VBN
in/IN
our/PRP$
analysis/NN
,/,
findings/NNS
of/IN
this/DT
study/NN
on/IN
the/DT
promoter/NN
region/NN
polymorphisms/NNS
(/(
−1547T＞C/NN
,/,
−644T＞C/NN
,/,
−625G＞C/NN
)/)
showed/VBD
no/DT
association/NN
signals/NNS
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/or/CC
HCC/NN
occurrence/NN
and/CC
is/VBZ
thus/RB
,/,
consistent/JJ
with/IN
one/CD
of/IN
the/DT
previous/JJ
studies/NNS
./.
====================
Among/IN
the/DT
six/CD
SNPs/NNS
that/DT
were/VBD
analyzed/VBN
for/IN
large/JJ
scale/JJ
genotyping/VBG
,/,
＋9194A＞G/NN
initially/RB
showed/VBD
an/DT
association/NN
signal/NN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
before/IN
multiple/JJ
testing/VBG
corrections/NNS
./.
====================
The/DT
polymorphism/NN
also/RB
demonstrated/VBD
a/DT
protective/JJ
effect/NN
on/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/CC
led/VBD
to/TO
the/DT
amino/NN
acid/NN
modification/NN
from/IN
lysine/NN
to/TO
glutamate/VB
./.
====================
Marusawa/NN
et/FW
al/JJ
./.
====================
has/VBZ
demonstrated/VBN
that/IN
BIRC5/NN
forms/NNS
complexes/NNS
with/IN
a/DT
cellular/JJ
protein/NN
called/VBN
hepatitis/NN
B/NN
X-interacting/JJ
protein/NN
(/(
HBXIP/NN
)/)
./.
====================
This/DT
protein/NN
’/CD
s/NNS
pro-caspase-9/NN
is/VBZ
activated/VBN
by/IN
Apaf1/NN
,/,
a/DT
cytoplasmic/JJ
protein/NN
recognized/VBD
for/IN
associating/VBG
the/DT
X/NN
protein/NN
of/IN
hepatitis/NN
B/NN
virus/NN
(/(
HBX/NN
)/)
and/CC
BIRC5/NN
./.
====================
Complexes/NNS
of/IN
BIRC5-HBXIP/NN
prevents/VBZ
the/DT
recruitment/NN
of/IN
components/NNS
that/IN
can/MD
initiate/VB
apoptosis/NN
(/(
Marusawa/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Moreover/RB
,/,
in/IN
another/DT
SNP/NN
study/NN
,/,
Jang/NN
et/FW
al/JJ
./.
====================
reported/VBN
that/IN
＋9194A＞G/NN
might/MD
be/VB
related/JJ
with/IN
cancer/NN
(/(
Jang/NN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
According/VBG
to/TO
the/DT
study/NN
if/IN
alteration/NN
of/IN
amino/NN
acid/NN
by/IN
＋9194A＞G/NN
in/IN
exon4/NN
affects/VBZ
protein/NN
formation/NN
,/,
then/RB
it/PRP
will/MD
also/RB
affect/VB
the/DT
interaction/NN
of/IN
HBXIP/NN
and/CC
BIRC5/NN
./.
====================
In/IN
this/DT
study/NN
,/,
＋9194A＞G/NN
initially/RB
showed/VBD
an/DT
association/NN
signal/NN
with/IN
clearance/NN
of/IN
HBV/NN
infection/NN
./.
====================
Although/IN
the/DT
signal/NN
disappeared/JJ
after/IN
multiple/JJ
testing/VBG
corrections/NNS
,/,
it/PRP
might/MD
provide/VB
valuable/JJ
meaning/VBG
to/TO
studies/NNS
on/IN
the/DT
function/NN
of/IN
BIRC5/NN
./.
====================
In/IN
summary/NN
,/,
we/PRP
have/VBP
identified/VBN
eight/CD
polymorphisms/NNS
in/IN
the/DT
human/JJ
BIRC5/NN
gene/NN
that/WDT
were/VBD
used/VBN
to/TO
locate/VB
six/CD
common/JJ
polymorphic/JJ
sites/NNS
selected/VBN
for/IN
largescale/JJ
genotyping/VBG
./.
====================
After/IN
conducting/VBG
a/DT
test/NN
on/IN
the/DT
functions/NNS
of/IN
the/DT
promoter/NN
region/NN
polymorphisms/NNS
,/,
statistical/JJ
analysis/NN
displayed/VBD
no/DT
association/NN
among/IN
polymorphisms/NNS
in/IN
the/DT
promoter/NN
region/NN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/or/CC
HCC/NN
occurrence/NN
./.
====================
In/IN
addition/NN
,/,
＋9194A＞G/NN
initially/RB
showed/VBD
an/DT
association/NN
signal/NN
with/IN
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/CC
led/VBD
to/TO
transformation/NN
of/IN
amino/NN
acid/NN
./.
====================
We/PRP
also/RB
found/VBD
that/IN
haplotype2/NN
and/CC
haplotype5/NN
initially/RB
showed/VBD
association/NN
signals/NNS
with/IN
HBV/NN
infection/NN
and/CC
the/DT
onset/NN
age/NN
of/IN
HCC/NN
analysis/NN
,/,
respectively/RB
./.
====================
However/RB
,/,
all/DT
association/NN
signals/NNS
disappeared/VBD
after/IN
multiple/JJ
testing/VBG
corrections/NNS
,/,
which/WDT
led/VBD
us/PRP
to/TO
conclude/VB
that/IN
there/EX
was/VBD
no/DT
association/NN
between/IN
BIRC5/NN
polymorphisms/NNS
and/CC
the/DT
clearance/NN
of/IN
HBV/NN
infection/NN
and/or/CC
HCC/NN
occurrence/NN
./.
====================
Although/IN
our/PRP$
pvalues/NNS
did/VBD
not/RB
undergo/VB
multiple/JJ
testing/VBG
corrections/NNS
,/,
results/VBZ
from/IN
this/DT
study/NN
might/MD
be/VB
useful/JJ
for/IN
future/JJ
researches/VBZ
which/WDT
should/MD
include/VBP
additional/JJ
investigation/NN
on/IN
the/DT
function/NN
and/or/CC
expression/NN
of/IN
the/DT
polymorphisms/NNS
of/IN
BIRC5/NN
./.
====================
